药物诱导的无菌性脑膜炎:对日本不良事件报告数据库的药监测分析
Sho Masago1,2, Kazumasa Kotake3, Kenta Yamaoka2,4
1Department of Pharmacy, Shinko Hospital, Kobe, Japan; masago.sho@shinkohp.or.jp.
In vivo (Athens, Greece)
|February 27, 2026
概括
药物诱导的无菌性脑膜炎 (DIAM) 的发病因药物类别而异. SARS-CoV-2 疫苗的发病速度很快,而免疫检查点抑制剂的发病时间较晚,这表明这种罕见的不良事件的机制不同.
科学领域:
- 药物监督 药物监督 药物监督
- 临床药理学 临床药理学
- 免疫学 免疫学 免疫学
背景情况:
- 药物诱导的无菌性脑膜炎 (DIAM) 是一种罕见但显著的不良事件.
- 识别致病原体和了解发病模式对于临床管理至关重要.
研究的目的:
- 使用日本不良药物事件报告 (JADER) 数据库识别与无菌性脑膜炎相关的药物.
- 分析不同药物类别的DIAM发作的时间模式.
主要方法:
- 在JADER数据库 (2004年4月 - 2024年10月) 中对无菌性脑膜炎不良事件的不成比例分析.
- 计算报告几率比率 (RORs) 以95%的置信区间来检测不成比例信号.
- 韦布尔分布分析,以评估 DIAM 对于已识别的药物出现的时间.
主要成果:
- 19种药物与无菌性脑膜炎有关,包括疫苗,免疫球蛋白产品,NSAID和免疫检查点抑制剂 (尼沃卢马布,伊皮利穆马布).
- 与SARS-CoV-2RNA疫苗相关的DIAM通常发生在接种疫苗后的几天内.
- 在nivolumab和ipilimumab后的DIAM发作延迟,与随机失败和免疫相关的不良事件一致.
结论:
- 在不同药物类别中,DIAM的发病模式显著不同,例如SARS-CoV-2RNA疫苗和免疫检查点抑制剂.
- 这些不同的发病时间表明DIAM背后存在不同的病理生理机制.
- 了解这些差异有助于对无菌性脑膜炎的差异诊断和临床治疗.
更多相关视频
相关概念视频
Pharmacovigilance
1.9K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.9K
Therapeutic Drug Monitoring: Affecting Factors
288
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
288
Therapeutic Drug Monitoring: Drug Analysis Methods
250
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
250
Analysis of Population Pharmacokinetic Data
872
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
872
Therapeutic Drug Monitoring: Overview and Classification
445
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
445
Drug toxicity: Idiosyncratic Reactions
66
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
66


